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Abstract Production of sufficient amounts of human pro-
teins is a frequent bottleneck in structural biology. Here we
describe an Escherichia coli-based cell-free system which
yields mg-quantities of human proteins in N-terminal fusion
constructs with the GB1 domain, which show significantly
increased translation efficiency. A newly generated E. coli
BL21 (DE3) RIPL-Star strain was used, which contains a
variant RNase E with reduced activity and an excess of rare-
codon tRNAs, and is devoid of lon and ompT protease
activity. In the implementation of the expression system we
used freshly in-house prepared cell extract. Batch-mode cell-
free expression with this setup was up to twofold more
economical than continuous-exchange expression, with
yields of 0.2–0.9 mg of purified protein per mL of reaction
mixture. Native folding of the proteins thus obtained is
documented with 2D [15N,1H]-HSQC NMR.
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Abbreviations
2-ME b-Mercaptoethanol
BMCF Batch mode cell-free
bp Base pairs
CECF Continuous-exchange cell-free
kDa Kilo-Dalton
DEPC Diethylpyrocarbonate
DHFR Dihydrofolate reductase
DTT Dithiothreitol
EDTA Ethylenediaminetetraacetic acid
FABP4 Adipocyte fatty acid-binding protein 4
FKBP Human peptidyl-prolyl cis–trans isomerase
FKBP1A
GB1 B1 domain of protein G from Streptococcus
sp
GILT c-Interferon-inducible lysosomal
thiol reductase
HSQC Heteronuclear single quantum coherence
IPTG Isopropyl-b-D-thiogalactopyranoside
LB Luria Bertani
MMCE Mitochondrial methylmalonyl-CoA
epimerase
MTHFS Methenyl-THF synthetase
OAc Acetate
PBS Phosphate-buffered saline
PCP2H Purkinje cell protein 2 homolog
ppiB Peptidyl-prolyl cis–trans isomerase B
PYG Phosphate/yeast extract/glucose
SDS-PAGE Sodium dodecyl-sulfate polyacrylamide gel
electrophoresis
SF20 Stromal cell-derived growth factor
T7 RNAP RNA polymerase from bacteriophage T7
TBS Tris-buffered saline
Introduction
In structural and functional studies of human proteins, the
production of sufficient amounts of soluble, active protein
is a frequent bottleneck. This is due to generally low yields
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of eukaryotic expression hosts such as yeast, insect or
mammalian cells, whereas the use of prokaryotic hosts
such as Escherichia coli is often limited by reduced protein
solubility due to misfolding or aggregation, or by protein
degradation through endogenous bacterial proteases. Here
we explore the use of cell-free expression for work with
small, soluble human proteins.
Cell-free expression has become popular in a variety of
different applications, as it allows expression of toxic
proteins (Xu et al. 2005), offers fast microliter-scale
screening for optimizing expression conditions, and
enables simple purification and easy scale-up (Sitaraman
and Chatterjee 2009). For NMR studies, low metabolic
activity of the cell extract further allows efficient stable-
isotope labeling without significant isotope scrambling
between amino acids (Ozawa et al. 2004; Staunton et al.
2006; Vinarov et al. 2006). Except for the use of complex
semi-continuous procedures that yielded milligram quan-
tities per mL of reaction mixture of some human proteins
(Vinarov et al. 2006), cell extracts from eukaryotic
organisms have been reported to provide only microgram
amounts of protein per mL reaction mixture (Endo et al.
1992; Kawasaki et al. 2003; Henshaw and Panniers 1983),
and major efforts are required to prepare the cell extract
(Ezure et al. 2006; Anderson et al. 1983). We therefore
decided to optimize an E. coli-based cell-free system for
production of milligram amounts of soluble human pro-
teins, in an attempt to take advantage of its high intrinsic
productivity and relatively simple preparative demands
(Kigawa et al. 2008; Michel-Reydellet et al. 2004; Etezady-
Esfarjani et al. 2007; Torizawa et al. 2004; Ozawa et al.
2004).
Materials and methods
Our protocol for cell-free protein expression includes that
the cell extract was home-made, both to ensure high
activity of the freshly prepared extract and for economic
reasons. Throughout all procedures used, we exercised
extreme care to avoid RNase contamination.
Generation of an E. coli BL21 (DE3) RIPL-Star strain
for S30 extract preparation
Escherichia coli BL21 (DE3) CodonPlus cells were grown
overnight in 5 mL LB medium, harvested by centrifuga-
tion, and the pACYC- and pSC101-based plasmids (3.5 and
4.7 kbp, respectively), which harbour genes encoding rare-
codon tRNAs, were isolated with a plasmid miniprep
(NucleoSpin Plasmid Kit, Macherey–Nagel). All culture
media and media plates were supplemented with 20 lg/mL
chloramphenicol and 20 lg/mL streptomycin, and they
were incubated at 37 C. Plasmids were separated on a
0.8 % agarose gel, extracted from the gel (QIAEXII, Qia-
gen), and co-transformed into E. coli BL21 (DE3) Star
cells (Stratagene). Positive transformants were used to
inoculate 5 mL LB cultures, which were then grown with
shaking to an OD600 of ca. 1.0. The cell suspensions were
supplemented to a final concentration of 30 % (v/v) with
glycerol and stored at -80 C in 1 mL aliquots, to be used
for inoculation of S30 extract cultures.
S30 extract preparation
The protocols proposed by Chen and Zubay (1983) and by
Kainosho and coworkers (Torizawa et al. 2004) were
adopted as the starting platform for obtaining cell extract
from the E. coli BL21 (DE3) RIPL-Star strain. All equip-
ment used for extract preparation was treated sequentially
with RNase-AWAY (Molecular BioProducts) and DEPC-
treated water and, unless stated otherwise, all solutions
other than the culture media were prepared with DEPC-
treated water. All preparative steps after cell harvest were
performed on ice, and centrifugation and dialysis were
carried out at 4 C.
9 L of PYG medium (5.6 g/L KH2PO4, 28.9 g/L
K2HPO4, 10 g/L yeast extract, and 1 % (w/v) glucose) for
the E. coli cultures was supplemented with 20 lg/mL
streptomycin and 20 lg/mL chloramphenicol, and cells
were grown to mid-log phase and harvested as described
(Etezady-Esfarjani et al. 2007). The cell pellet was washed
twice by resuspending in 500 mL S30 buffer (10 mM Tris-
OAc at pH 8.2, 60 mM KOAc, 14 mM Mg(OAc)2,
7.15 mM 2-mercaptoethanol, 1 mM DTT) using a Polytron
PT-3100 cell homogenizer at 3,500 rpm followed by cen-
trifugation. The washed cell pellet was resuspended in
2 mL S30 buffer per gram of cells, followed by cell dis-
ruption with a single passage through a French Press at
16000 psi (Thermo Electron Corporation). The lysate was
centrifuged twice for 30 min at 30,0009g, and each time
the supernatant was carefully pipetted into a new tube. The
cleared lysate was then incubated for 40 min at 30 C
with 0.25 volumes pre-incubation mixture (293.3 mM
Tris-OAc at pH 8.2, 84 mM PEP, 13.17 mM ATP,
9.24 mM Mg(OAc)2, 4.4 mM DTT, 40 lM of each of the
20 proteinogenic amino acids, 6.67 U/mL of pyruvate
kinase). After 10 min of centrifugation at 4,0009g, the pre-
incubation supernatant was dialyzed for 1.5 h with a
12–14 kDa MWCO SpectraPor4 dialysis membrane, first
against 1 L of S30 buffer and then overnight against 2 L of
fresh S30 buffer. The extract was finally concentrated in a
10 kDa MWCO Amicon Ultra-15 ultrafiltration device
(Millipore) to an A260 of 350–450, and it was cleared by
centrifugation for 10 min at 4,0009g to remove insoluble
particles. 500 lL aliquots of cell extract were frozen by
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immersion into liquid nitrogen and stored at -80 C until
needed.
Preparation of the vectors pCFX1 and pCFX3
and cloning of target genes
The B1 domain of the protein G was PCR-amplified from
pET30a-GB1 (Zhou et al. 2001), using the 50- and 30-oli-
gonucleotide primers 50-ATA AGA ATG CGG CCG CCA
GTA CAA ACT GAT CCT GAA CGG-30 and 50-GGA
ATT CCA TAT GGC TGC CGC GCG GCA CCA GGC
CGC TGC TTT CGG TAA CGG TGA AGG TTT TGG-30.
It was then inserted into pIVEX2.4, using the NotI and
NdeI restriction sites to yield the vector pCFX1. The vector
pCFX3 was prepared from pCFX1 by site-directed muta-
genesis (QuikChange II XL, Stratagene), using 50-CC GAA
AGC AGC GGC GAA AAC CTG TAC TTC CAG AGC
GGC AGC CAT ATG ACC-30 and 50-GGT CAT ATG
GCT GCC GCT CTG GAA GTA CAG GTT TTC GCC
GCT GCT TTC GG-30 as 50- and 30-oligonucleotide
primers, respectively.
The cDNA encoding the human target proteins was
purchased from ImaGenes (Berlin). pET21-DHFR was a
gift of Dr. A. Horwich. All target proteins were amplified
by PCR (Hotstart) from their respective source DNA, using
the oligonucleotide primers (Microsynth) listed in Table
S1, and were inserted into pIVEX2.4d (Roche) and pCFX1
using the NdeI and BamHI (NEB) restriction sites. All
constructs were sequence-verified at Microsynth (Switzer-
land). Plasmids for cell-free expression were prepared
using the Qiagen Plasmid Maxi Kit (Qiagen).
Cell-free expression
With the exception of the S30 extract, all stock solutions
required for cell-free synthesis were stored in appropriate
aliquots at -20 C and were thawed on ice prior to use.
The reaction mixtures were prepared with the components
listed in Tables S2 and S3. T7 RNA polymerase was
expressed and purified as previously described (Etezady-
Esfarjani et al. 2007). Analytical-scale batch-mode reac-
tions (50–100 lL) were carried out in 1.5 mL tubes in a
Thermomixer Comfort (Eppendorf) at 30 C for 2.5 h
with gentle agitation; preparative-scale reactions (10 mL)
were incubated in 15 mL tubes. For continuous-exchange
cell-free expression, the reaction solution was transferred
to a 50 kDa MWCO SpectraPor Float-A-Lyzer (Spectrum
Labs) that was completely immersed in a 14 mL round-
bottom culture tube (Greiner Bio-One) containing a ten-
fold excess of feeding solution (Table S4). The reaction
chamber was sealed tightly with parafilm and was incu-
bated for 20 h at 30 C with gentle agitation. After the
reaction was completed, the reaction and feeding
solutions were both pooled and used for subsequent
purification.
Monitoring cell-free expression mixtures
with SDS-PAGE and Western Blot
After cell-free expression, soluble and insoluble protein
was separated by centrifugation (3 min at 14,0009g). For
protein production we worked only with the soluble frac-
tion. 50 lL of the supernatant was mixed with 500 lL of
acetone at -20 C, the mixture was incubated for 5 min on
ice, and centrifuged for 5 min at 14,0009g. The pellet was
collected and residual acetone removed in an airstream
before resuspension in 100 lL SDS-PAGE loading buffer
(150 mM Tris–HCl at pH 6.8, 6 % (v/v) 2-ME, 1.2 % (v/v)
SDS, 30 % (v/v) glycerol, bromophenol blue) for analysis
by SDS-PAGE.
To investigate the impact of fusion with the GB1-
domain, we also analyzed the pellet containing the protein
which precipitated during the cell-free reaction. The pellet
was washed by re-suspension in 100 lL water, collected
again by centrifugation for 5 min at 14,0009g, and dis-
solved in 100 lL SDS-PAGE loading buffer.
The solutions in SDS-PAGE loading buffer were incu-
bated at 95 C for 3 min, which was followed by vortexing
for 10 min and clearing by centrifugation for 3 min at
12,0009g. The resulting samples were applied either on
NuPAGE 4–12 % Bis–Tris gels (Invitrogen) using MES
running buffer (50 mM MES, 50 mM Tris, 1 mM EDTA,
0.1 % (w/v) SDS), or on 12 % SDS-Tris-Laemmli gels
(Laemmli 1970) using a Tris-Tricine running buffer
(100 mM Tris, 100 mM Tricine, 0.1 % (w/v) SDS).
Western blots were prepared following the protocol by
Towbin et al. (Towbin et al. 1979) and were incubated
sequentially with 1:5,000 diluted murine anti-polyHistidine
antibody (Sigma) and anti-mouse IgG (Fc specific) alkaline
phosphatase conjugate (Sigma). Protein bands were visu-
alized in alkaline phosphatase reaction buffer (100 mM
Tris–HCl at pH 9.5, 100 mM NaCl, 5 mM Mg(Cl)2) sup-
plemented with 100 lM BCIP (Roche) and 100 lM NBT
(Sigma).
Purification of the cell-free expression product
All purification steps were performed at 4 C, using an
Aekta-prime FPLC system (GE Healthcare) equipped with
A280 and conductivity-measurement monitoring devices.
The protein solutions obtained after clearing the pre-
parative-scale cell-free reaction mixtures were applied to a
5 mL HisTrap HP column (GE Healthcare) pre-equili-
brated with buffer A (50 mM sodium phosphate at pH 7.2,
30 mM imidazole, 500 mM NaCl, 10 lM NaN3). After
washing with 100 mL buffer A, the target protein was
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eluted in a 100 mL linear gradient of 30–500 mM imid-
azole in buffer A. Fractions with absorbance at 280 nm
were subjected to SDS-PAGE analysis.
Proteolytic cleavage of the GB1 fusion domain
Initially, the GB1 fusion domain was cleaved with
thrombin. For this, ten units of thrombin were added per
mg of fusion protein, and the cleavage reaction was dia-
lyzed either for 4 h at room temperature or overnight at
4 C against 2 L of PBS (11.8 mM sodium phosphate at pH
7.4, 4.4 mM KCl, 136.9 mM NaCl, 10 lM NaN3) with a
12–14 kDa MWCO SpectraPor4 dialysis membrane. The
reaction was quenched with 1 mM PMSF, and the solution
was passed through a 5 mL HisTrap HP column pre-
equilibrated with buffer A. The flow-through containing
the target protein was collected.
Alternatively, we have used TEV protease for fusion
protein cleavage. For this, 0.1 mg of (His)6-tagged TEV
was added to each mg of purified fusion protein and the
cleavage reaction was dialyzed overnight with a 3.5 kDa
MWCO SpectraPor3 or a 12–14 kDa MWCO SpectraPor4
dialysis membrane against 2 L of TEV cleavage buffer
(50 mM sodium phosphate at pH 7.4, 100 mM NaCl,
2 mM 2-mercaptoethanol, 0.5 mM EDTA, 10 lM NaN3).
After cleavage the solution was passed through a 5 mL
HisTrap HP column (GE Healthcare) and the flow-through
containing the desired target protein was collected.
For production of TEV protease, the plasmid pET19-
TEV, obtained as a gift from Dr. E. Weber-Ban, was trans-
formed into E. coli BL21 (DE3) CodonPlus cells. Cells were
grown at 37 C in LB medium containing 100 mg/L car-
benicillin to an OD600 of ca. 0.6–0.8 and were then induced
with 0.125 mM IPTG for 12 h at 20 C. The cell pellet
collected by centrifugation was resuspended in 80 mL buffer
A (50 mM sodium phosphate at pH 7.4, 30 mM imidazole,
500 mM NaCl) and passed four times through the cell
cracker at 75 psi. After centrifugation at 30,0009g and 4 C
for 30 min, the supernatant was applied to a HisPrep FF
16/10 column (GE Healthcare). After washing with 100 mL
buffer A, TEV protease was eluted with a 150 mL linear
gradient from buffer A to buffer B (50 mM sodium phos-
phate at pH 7.4, 500 mM imidazole, 500 mM NaCl). The
fractions containing TEV protease were pooled and dialyzed
overnight at 4 C with a 12–14 kDa MWCO SpectraPor4
dialysis membrane against buffer C (25 mM sodium phos-
phate at pH 7.5, 100 mM NaCl, 2 mM EDTA, 2 mM DTT,
10 lM NaN3). The buffer was then exchanged with 2 L of
new buffer C and dialysis was continued for 8 h. The
resulting solution was concentrated in a 10 kDa MWCO
Vivaspin-20 ultracentrifugation device to ca. 0.8 mg/mL,
diluted with glyercol to a final concentration of 0.5 mg/mL
TEV, and stored at -80 C until needed.
NMR sample preparation
For each protein in Table S1, a 10 mL BMCF reaction with
15N-labeled amino acids (Spectra Stable Isotopes) was set
up. The purified target proteins were dialyzed overnight at
4C against 2 L of NMR buffer (depending on the protein:
between 20 and 50 mM sodium phosphate, 20 and
100 mM sodium chloride, 100 lM EDTA, 10 lM NaN3,
5 % (v/v) D2O, with the pH of the solution adjusted in
accordance with the pI of the protein, and DTT or 2-ME
added for proteins containing cysteine residues). Protein
constructs with a molecular mass below 15 kDa were
dialyzed in a 8 kDa MWCO SpectraPor Biotech RC
membrane, while larger constructs were dialyzed in
12–14 kDa MWCO SpectraPor4 membranes (both from
Spectrum Labs). After overnight dialysis, the dialysis
tubing was transferred into 2 L of fresh NMR buffer for
another 4 h. The protein solution was then concentrated
using a 3 kDa or 10 kDa MWCO ultracentrifugation
device (Millipore) to a final volume of ca. 500 lL, sup-
plemented with 5 % (v/v) D2O and transferred into a 5TA
NMR sample tube (Armar Chemicals).
NMR spectroscopy
NMR measurements were performed either on a Bruker
DRX-500 spectrometer equipped with a Cryoprobe, or on
Bruker DRX-600 and DRX-750 spectrometers equipped
with room-temperature triple resonance probes with shiel-
ded z-gradient coils. The measurement temperature was in
the range from 20 to 37 C, depending on the protein.
Spectra were processed either with the program PROSA
(Gu¨ntert et al. 1992) or with TOPSPIN 2.0 (Bruker-Bio-
spin), and spectral analysis was carried out using the pro-
gram CARA (Keller 2004).
Results and discussion
S30 cell extract preparation
For cell extract preparation we generated the new strain
E. coli BL21 (DE3) RIPL-Star by introducing two plasmids
that encode rare-codon tRNAs from E. coli BL21 (DE3)
CodonPlus cells into competent E. coli BL21 Star cells
(Fig. 1). This strain contains basic features that have pre-
viously been shown to be favorable for cell-free synthesis.
This includes that the strain has reduced RNase E activity
(Jermutus et al. 1998; Kigawa et al. 2004) to increase
mRNA half-life (Pratt 1984; Torizawa et al. 2004), and
is deficient in both OmpT and lon protease activities
to reduce proteolytic degradation of the target protein
(Kigawa et al. 2004).
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The S30 extract preparation was based on protocols
proposed by Nirenberg and Matthaei (1961) and Chen and
Zubay (1983). Adjustments include that the cells are har-
vested, washed and disrupted within 1 day, followed by
pre-incubation of the cell extract and overnight dialysis
against S30 buffer (Fig. 2). Thereby, pre-incubation of the
cell-extract was shortened from 80 to 40 min and the
incubation temperature was reduced from 37 to 30 C, so
as to reduce exposure of the cell extract to conditions that
could lead to degradation of the translation machinery.
After an overnight pre-culture, highly active cell extract
was produced in one working day, with a yield of about
2.5 mL cell extract per liter of cell culture (Fig. 2).
Expression vectors and protein purification
Two new cell-free expression vectors, pCFX1 and pCFX3,
containing a 55-amino acid N-terminal GB1-solubility
domain with a flexible linker to the target protein were
prepared, starting from the commercially available
pIVEX2.4 vector (Fig. 3). The vectors provide a multiple-
cloning site (MCS) for insertion of target genes with the
use of common restriction enzymes, and enable proteolytic
removal of either the (His)6-tagged GB1-domain with
thrombin (pCFX1) or tobacco etch virus protease (pCFX3),
or the (His)6-tag with Factor Xa protease.
Cell-free expression of human proteins
Ten human proteins intended for NMR investigation, with
molecular mass below 25 kDa, were used in this study
(Table S1), including the four proteins DHFR, complexin-1,
ppiB and FABP4 with known structures (Stockman et al.
1992; Chen et al. 2002; Mikol et al. 1994; Marr et al. 2006).
The proteins were cloned into both the pIVEX2.4 and
pCFX1 vectors. Initially, 100 lL small-scale test expres-
sions were carried out for 2.5 h at 30 C, and the soluble and
insoluble protein products were analyzed with SDS-PAGE
and Western blot (Fig. 4). Compared to pIVEX2.4, cell-free
protein expression using the pCFX1 vector resulted in up to
fivefold increased yields (Fig. 4a, b). With the sole exception
of the methenyl-THF synthetase, the presence of the GB1
tag, which is normally considered to enhance solubility, was
Fig. 1 Flow diagram of the preparation of the E. coli BL21 (DE3)
RIPL-Star strain
Dialysis against 2L S30 buffer
 (overnight)
200 mL pre-culture with E. coli RIPL Star cells
                               (overnight)
9 L main culture inoculated with pre-culture.
Cells grown to an OD600 of ca. 0.8.
Cells harvested by centrifugation.
Cells washed three times with S30 buffer. 
Cells disrupted by one passage through French Press.
Cell debris removed by centrifugation.
Preincubation at 30°C for 40 min.
2x60 min dialysis against 2x500 mL S30 buffer.
Centricon ultrafiltration for extract concentration.
Stored at -80°C.
0
10
13
19
29
31
time [h]
Fig. 2 Flow diagram of the S30 cell extract preparation. On the left
the approximate times needed for individual steps of the protocol are
indicated. Bullets indicate the manipulations that require constant
involvement of the operator
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found not to influence the amount of insoluble protein
(Fig. 4c, d). We conclude that although the GB1-fusion
results in increased yields of soluble protein, as expected
(Zhou et al. 2001), it also leads to increased total protein
synthesis due to enhanced translation efficiency (Butt et al.
1989; Laursen et al. 2005; Goerke and Swartz 2008).
For a quantitative comparison, 10 mL batch-mode reac-
tions of the proteins ppiB, FABP4, SF20, and MTHFS were
set up with both pIVEX2.4 and pCFX1 constructs. After
purification the protein yields were quantified by measuring
the UV absorption at 280 nm. In all cases the protein yield was
increased at least twofold when the targets were expressed as
GB1 fusion proteins in the pCFX1 vector (Figure S1).
Purification of the cell-free expression product, proteo-
lytic removal of the GB1 domain or the (His)6-tag (Fig. 3),
and final purification of the target protein were performed
as described in Materials and Methods. For most of the
targets the fusion construct with the GB1 domain as well as
the free protein were prepared.
NMR characterization of proteins from cell-free
expression
The 2D [15N,1H]-HSQC spectra of nine proteins are shown
in Fig. 5. No spectrum of GILT could be obtained because
the protein aggregated when the solution was concentrated
after purification. For some of the proteins the GB1-
domain, which usually stabilizes the proteins in solution,
was not removed, since it did not interfere with the analysis
of the spectrum. For dihydrofolate reductase (Fig. 5a)
NMR assignments are available (Stockman et al. 1992).
Comparison of the cell-free produced dihydrofolate
reductase in complex with methotrexate with the literature
data showed that the native fold, capable of binding
methotrexate, was obtained after cell-free expression.
The 2D [15N,1H]-HSQC spectra of the proteins shown in
Fig. 5b–f, all show chemical shift dispersion typical of
globular domains. In the GB1-fusion constructs the sub-
spectrum of this domain can readily be recognized.
Fig. 3 Cell-free expression vectors pCFX1 and pCFX3. Based on the
commercially available vector pIVEX2.4, they both contain a
multiple-cloning site (MCS) for insertion of the target gene and a
GB1 solubility domain which precedes the MCS. The GB1 domain
can be cleaved either with thrombin (pCFX1) or with TEV (pCFX3).
The N-terminal hexahistidine tag can be proteolytically removed with
Factor Xa. T7 RNAP is the RNA polymerase from bacteriophage T7,
RBS the ribosomal binding site, and ATG the start codon for
translation
Fig. 4 Comparison of cell-free expression yields for the 10 targets of
Table S1 without and with N-terminal fusion with the GB1 domain.
Shown are Western blot analyses of the soluble protein obtained from
cell-free expression using either the pIVEX2.4 vector (a) or the
pCFX1 vector (b). c, d SDS-PAGE analyses of the insoluble protein
obtained from the same cell-free expression reactions with the
pIVEX2.4 (c) or pCFX1 (d) vectors. The reactions were carried out
for 2.5 h at 30 C with gentle agitation. The synthesis mixture for
production of dihydrofolate reductase (lane 10) was supplied with
440 lM methotrexate prior to reaction initiation. The applied sample
volume on each lane corresponds to 2.5 lL reaction mixture in a and
b, and to 5 lL reaction mixture in c and d. Arrows indicate the bands
corresponding to the target proteins. Symbols used: M protein
molecular weight marker; N negative control; P positive control
protein FKBP; 1 MARCKS-related protein (macrophage myristoy-
lated alanine-rich C kinase substrate); 2 purkinje cell protein
2 homolog; 3 methenyl-THF synthetase (5-formyltetrahydrofolate
cyclo-ligase); 4 c-interferon-inducible lysosomal thiol reductase;
5 mitochondrial methylmalonyl-CoA epimerase; 6 uncharacterized
human protein C19orf10 (stromal cell-derived growth factor SF20);
7 adipocyte fatty acid-binding protein 4; 8 peptidyl-prolyl cis–trans
isomerase B; 9 complexin-1; 10 dihydrofolate reductase
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For the proteins complexin-1, MARCKS-related protein,
and PCP2H (Fig. 5g–i), which contain a high content of
polar and charged amino acids and a low percentage of
large hydrophobic residues, characteristic of intrinsically
unstructured proteins (Dyson and Wright 2005), the pro-
gram GlobPlot (http://globplot.embl.de/) (Linding et al.
2003) predicts that these proteins are mostly disordered. In
agreement with this prediction, all three proteins give rise
to 2D [15N,1H]-HSQC spectra with small dispersion of the
1H chemical shifts, except that the well-dispersed spectrum
of GB1 is seen in the fusion constructs of complexin-1 and
the GB1-MARCKS-related protein with this domain.
Economic considerations
The tables S6 and S7 show that with the use of in-house
prepared cell extract, the expense for chemicals in the
present cell-free system is dominated by the isotope-
labeled amino acids. In this context we compared cost
effectiveness of the popular continuous-exchange cell-free
Fig. 5 2D [15N,1H]-HSQC
spectra of human proteins
prepared by cell-free expression
with 15N-labeled amino acids,
where for some proteins the
fusion construct with GB1 was
measured. a 325 lM [u-15N]-
dihydrofolate reductase in
complex with methotrexate at
20 C. b 150 lM [u-15N]-GB1-
methylmalonyl-CoA epimerase
at 37 C. c 165 lM [u-15N]-
GB1-MTHFS at 37 C.
d 250 lM [u-15N]-GB1-stromal
cell-derived growth factor SF20
at 25 C. e 360 lM [u-15N]-
peptidyl-prolyl cis–trans
isomerase B at 20 C. f 400 lM
[u-15N]-GB1-FABP4 in the
presence of 1 mM unlabeled
SDS at 20 C. g 500 lM
[u-15N]-GB1-complexin-1 at
20 C. h 600 lM [u-15N]-GB1-
MARCKS-related protein at
20 C. i 200 lM [u-15N]-
purkinje cell protein-2 homolog
at 20 C. The spectra a–f were
recorded at 750 MHz, g, h at
500 MHz, and i at 600 MHz
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(CECF) expression mode (Chekulayeva et al. 2001;
Schwarz et al. 2007; Torizawa et al. 2004; Vinarov et al.
2006; Ozawa et al. 2004; Kigawa et al. 2004; Spirin 2004)
with batch mode synthesis.
To compare productivity and costs, we performed both
CECF and BMCF expressions of the soluble protein FKBP
(Etezady-Esfarjani et al. 2007). Using CECF, 2 mg of
purified protein was obtained per mL reaction mixture,
while 0.4 mg of purified protein per mL reaction mixture
was obtained using BMCF. However, in spite of the higher
productivity, CECF was found to be twofold more expen-
sive than BMCF for the preparation of 1 mg of 13C,15N-
labeled FKBP. The higher cost resulted primarily from the
increased quantities of labeled amino acids used (Table
S7). In addition, based on indirect evidence such as loss of
enzyme activity in the expression mixture, we suspect that
the prolonged incubation of the protein at 30–37 C in the
highly crowded protein environment of the reaction mix-
ture may lead to protein inactivation or precipitation in the
CECF assay. In BMCF, the reaction time is shorter, so that
after 2.5 h the target protein can be transferred to a
molecular environment that supports the integrity and sta-
bility of the target protein.
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